Bud Genius Adds Financial Expert to Executive Advi
Post# of 5949
http://marijuanaspeculator.com/bud-genius-add...y-board-2/
Posted on April 2, 2015 by
By Ryan Allway
Bud Genius Inc. (), a leading cannabis laboratory and branding specialist, recently announced the addition of Dr. Peter Wilson, Ph.D., to its Executive Advisory Board. Dr. Wilson is a well-known and highly-respected expert in accounting, financial reporting, and business law with over 25 years of experience in corporate finance and 19 years at Duke University’s Fuqua School of Business.
“We are pleased to have Dr. Wilson join the company’s Executive Advisory Board and look forward to his contributions,” said Bud Genius Inc. CEO Angel Stanz in a press release announcing Dr. Wilson’s appointment. “As an expert in corporate finance, accounting, and financial reporting, Dr. Wilson will provide expertise in areas that can profoundly impact the future of our company.”
The move comes shortly after the company’s landmark agreement to acquire Evergreen Licensing. As the exclusive licensor of Tommy Chong marijuana, hemp, and cannabis-related products, the acquisition provides the company with a unique branding opportunity within the multi-billion dollar industry. Under the terms, the firm will manage licensing and distribution of branded products in California.
Moving forward, management plans to continue pursuing several business objectives throughout 2015, including the launch of its new mobile app and further celebrity licensing deals from media, sports, and entertainment genres. The company also plans to change its ticker symbol to better reflect its endeavors. Shareholders and investors interested in company’s current and future revenue drivers, including Marijuana Testing and Profiling, Licensing and Branding, Distribution and Supply Chain Optimization, and Healthcare Delivery Technology will find additional information at www.BGMedtech.com and www.BudGenius.com.
The post Bud Genius Adds Financial Expert to Executive Advisory Board appeared first on CannabisFN.